Format

Send to

Choose Destination
J Proteome Res. 2015 Sep 4;14(9):3621-34. doi: 10.1021/pr5010345. Epub 2015 Jul 22.

Computational and Mass-Spectrometry-Based Workflow for the Discovery and Validation of Missing Human Proteins: Application to Chromosomes 2 and 14.

Author information

1
Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), IPHC, Université de Strasbourg, CNRS, UMR7178 , 25 Rue Becquerel, 67087 Strasbourg, France.
2
CALIPHO Group, SIB-Swiss Institute of Bioinformatics, CMU , rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.
3
Department of Human Protein Sciences, Faculty of Medicine, rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.
4
CEA, DSV, iRTSV, Laboratoire de Biologie à Grande Echelle, 17 rue des martyrs, Grenoble, F-38054, France.
5
INSERM U1038 , 17, rue des Martyrs, Grenoble F-38054, France.
6
Université Grenoble , Grenoble F-38054, France.
7
CNRS UMR5089 Institut de Pharmacologie et de Biologie Structurale, 118 route de Narbonne, 31077 Toulouse, France.
8
Université de Toulouse , 205, route de Narbonne, 31077 Toulouse, France.

Abstract

In the framework of the C-HPP, our Franco-Swiss consortium has adopted chromosomes 2 and 14, coding for a total of 382 missing proteins (proteins for which evidence is lacking at protein level). Over the last 4 years, the French proteomics infrastructure has collected high-quality data sets from 40 human samples, including a series of rarely studied cell lines, tissue types, and sample preparations. Here we described a step-by-step strategy based on the use of bioinformatics screening and subsequent mass spectrometry (MS)-based validation to identify what were up to now missing proteins in these data sets. Screening database search results (85,326 dat files) identified 58 of the missing proteins (36 on chromosome 2 and 22 on chromosome 14) by 83 unique peptides following the latest release of neXtProt (2014-09-19). PSMs corresponding to these peptides were thoroughly examined by applying two different MS-based criteria: peptide-level false discovery rate calculation and expert PSM quality assessment. Synthetic peptides were then produced and used to generate reference MS/MS spectra. A spectral similarity score was then calculated for each pair of reference-endogenous spectra and used as a third criterion for missing protein validation. Finally, LC-SRM assays were developed to target proteotypic peptides from four of the missing proteins detected in tissue/cell samples, which were still available and for which sample preparation could be reproduced. These LC-SRM assays unambiguously detected the endogenous unique peptide for three of the proteins. For two of these, identification was confirmed by additional proteotypic peptides. We concluded that of the initial set of 58 proteins detected by the bioinformatics screen, the consecutive MS-based validation criteria led to propose the identification of 13 of these proteins (8 on chromosome 2 and 5 on chromosome 14) that passed at least two of the three MS-based criteria. Thus, a rigorous step-by-step approach combining bioinformatics screening and MS-based validation assays is particularly suitable to obtain protein-level evidence for proteins previously considered as missing. All MS/MS data have been deposited in ProteomeXchange under identifier PXD002131.

KEYWORDS:

Human Proteome Project (C-HPP); LC−SRM assays; bioinformatics; mass spectrometry; missing proteins identification

PMID:
26132440
DOI:
10.1021/pr5010345
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center